Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy
Eleonora Prodi,Dario Neri,Roberto De Luca
DOI: https://doi.org/10.2147/ott.s480787
IF: 4
2024-09-01
OncoTargets and Therapy
Abstract:Eleonora Prodi, 1, 2 Dario Neri, 3, 4 Roberto De Luca 1 1 Philochem AG, Otelfingen, 8112, Switzerland; 2 University of Trento, Italy, CiBIO (Department of Cellular, Computational and Integrative Biology), Povo, 38123, Trento; 3 Philogen Spa, Siena, 53100, Italy; 4 Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerland Correspondence: Dario Neri, Philogen Spa, Piazza La Lizza 7, Siena, 53100, Italy, Email Roberto De Luca, Philochem AG, Philogen Group, Libernstrasse 3, Otelfingen, CH-8112, Switzerland, Tel +41-43-5448818, Email Recombinant cytokine products have emerged as a promising avenue in cancer therapy due to their capacity to modulate and enhance the immune response against tumors. However, their clinical application is significantly hindered by systemic toxicities already at low doses, thus preventing escalation to therapeutically active regimens. One promising approach to overcoming these limitations is using antibody-cytokine fusion proteins (also called immunocytokines). These biopharmaceuticals leverage the targeting specificity of antibodies to deliver cytokines directly to the tumor microenvironment, thereby reducing systemic exposure and enhancing the therapeutic index. This review comprehensively examines the development and potential of antibody-cytokine fusion proteins in cancer therapy. It explores the molecular characteristics that influence the performance of these fusion proteins, and it highlights key findings from preclinical and clinical studies, illustrating the potential of immunocytokines to improve treatment outcomes in cancer patients. Recent advancements in the field, such as novel engineering strategies and combination strategies to enhance the efficacy and safety of immunocytokines, are also discussed. These innovations offer new opportunities to optimize this class of biotherapeutics, making them a more viable and effective option for cancer treatment. As the field continues to evolve, understanding the critical factors that influence the performance of immunocytokines will be essential for successfully translating these therapies into clinical practice. Keywords: antibody-cytokine fusion proteins, cancer therapy, activity on demand, dual-cytokine products Cytokines are small regulatory proteins, which are crucial for modulating the activity of the immune system. These polypeptides are generally secreted by immune cells such as macrophages, B lymphocytes, and T lymphocytes, as well as stromal cells and endothelial cells under specific conditions. Cytokines primarily act via autocrine and paracrine mechanisms by binding with high specificity and affinity to cognate receptors on target cells. This interaction may trigger signaling cascades that influence immune responses, cell maturation, migration, and death. 1 In the context of cancer, cytokines may contribute to both tumor suppression and tumor progression. For example, pro-inflammatory cytokines such as interleukin-2 (IL-2) enhance immune surveillance and boost anti-tumor responses by stimulating T-cells and natural killer cells. 2 By contrast, cytokines secreted by tumor cells and stromal cells in the tumor microenvironment (TME), like interleukin-6 (IL-6) and interleukin-10 (IL-10), may drive progression by promoting tumor cell proliferation, survival, angiogenesis, and metastasis. 3 Considering their involvement in numerous physiological and pathological conditions, cytokines have been investigated as standalone therapies and as targets for blocking agents. Interleukin-2 marked a significant chapter in the history of cancer immunotherapy. Originally identified in the late 1970s for its potent ability to stimulate the growth of T-cells, it was rapidly investigated as a therapeutic agent. 4 IL-2 is naturally produced by activated T cells and promotes the proliferation and activation of T cells and natural killer (NK) cells. The biological activity of IL-2 is mediated through the interaction with its cognate receptor (IL2R), which can be expressed as a high-affinity trimeric form composed of α (CD25), β (CD122), and γ (CD132) chains or as a low-affinity dimeric form with only the β and γ chains. The high-affinity IL2R is predominantly expressed on regulatory T cells (Tregs) and activated T cells. By contrast, the low-affinity receptor is typically found on resting T cells and most NK cells. 5,6 FDA approval of recombinant IL2 (Proleukin ® ) was granted in 1992 for treating metastatic renal cell carcinoma and later extended in 1998 for metastatic melanoma. 7–9 Proleukin is typically administered at 600,000 to 720,000 IU/kg as i.v. bolus every 8 hours for 14 consecutive doses over 5 days. Despi -Abstract Truncated-
oncology,biotechnology & applied microbiology